Cargando…

Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay

We evaluated three newly synthesized B-lactam hybrid homo-aza-steroidal alkylators (ASA-A, ASA-B and ASA-C) for their PARP1/2 inhibition activity and their DNA damaging effect against human ovarian carcinoma cells. These agents are conjugated with an alkylating component (POPA), which also served as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikoleousakos, Nikolaos, Dalezis, Panagiotis, Polonifi, Aikaterini, Geromichalou, Elena G., Sagredou, Sofia, Alifieris, Constantinos E., Deligiorgi, Maria V., Sarli, Vasiliki, Trafalis, Dimitrios T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394033/ https://www.ncbi.nlm.nih.gov/pubmed/34440232 http://dx.doi.org/10.3390/biomedicines9081028

Ejemplares similares

Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma
por: Dalezis, Panagiotis, et al.
Publicado: (2020)

Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation
por: Trafalis, Dimitrios T., et al.
Publicado: (2021)

3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha
por: Sagredou, Sofia, et al.
Publicado: (2020)

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden
por: Sagredou, Sofia, et al.
Publicado: (2021)

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
por: Deligiorgi, Maria V., et al.
Publicado: (2021)

8-Hydroxy-2’-Deoxyguanosine and 8-Nitroguanine Production and Detection in Blood Serum of Breast Cancer Patients in Response to Postoperative Complementary External Ionizing Irradiation of Normal Tissues
por: Verigos, Kosmas E., et al.
Publicado: (2020)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

In silico study of potential antiviral activity of copper(II) complexes with non–steroidal anti–inflammatory drugs on various SARS–CoV–2 target proteins
por: Geromichalou, Elena G., et al.
Publicado: (2022)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
por: Agarwal, Ashok, et al.
Publicado: (2009)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
por: Zhang, Zhimin, et al.
Publicado: (2020)

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA
por: Hirota, Kouji, et al.
Publicado: (2022)

Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
por: Altmeyer, Matthias, et al.
Publicado: (2009)

Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli
por: Boamah, Ernest K., et al.
Publicado: (2012)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
por: Noël, Georges, et al.
Publicado: (2003)

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
por: Fernández-Marcelo, Tamara, et al.
Publicado: (2014)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses
por: Song, Junqi, et al.
Publicado: (2015)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
por: Ström, Cecilia E., et al.
Publicado: (2011)

PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions
por: Catara, Giuliana, et al.
Publicado: (2017)

Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice
por: Piskunova, Tatiana S., et al.
Publicado: (2008)

Poly(ADP‐ribose)‐mediated interplay of XPA and PARP1 leads to reciprocal regulation of protein function
por: Fischer, Jan M. F., et al.
Publicado: (2014)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
por: Sargazi, Saman, et al.
Publicado: (2021)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
por: Gu, Zongying, et al.
Publicado: (2019)

Computational Bioprospecting Guggulsterone against ADP Ribose Phosphatase of SARS-CoV-2
por: Kciuk, Mateusz, et al.
Publicado: (2022)

Gemcitabine Induces Poly (ADP-Ribose) Polymerase-1 (PARP-1) Degradation through Autophagy in Pancreatic Cancer
por: Wang, Yufeng, et al.
Publicado: (2014)

Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
por: Shin, Hyeon-Jun, et al.
Publicado: (2015)

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
por: Gravells, Polly, et al.
Publicado: (2018)

Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1’-phosphatase
por: Webb, Thomas E., et al.
Publicado: (2020)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
por: Oliveira, Jennifer L., et al.
Publicado: (2022)

HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP-ribose modifications
por: Langelier, Marie-France, et al.
Publicado: (2021)

Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
por: Gagné, Jean-Philippe, et al.
Publicado: (2008)

Molecular Bases of Catalysis and ADP-Ribose Preference of Human Mn(2+)-Dependent ADP-Ribose/CDP-Alcohol Diphosphatase and Conversion by Mutagenesis to a Preferential Cyclic ADP-Ribose Phosphohydrolase
por: Cabezas, Alicia, et al.
Publicado: (2015)

Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53
por: Baumann, Cindy, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6uttgqh9a5gv7dteei2v4n71jk